Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738887) titled 'Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations' on July 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The Lymphoma Academic Research Organisation

Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Intervention: Drug: Ibrutinib Oral Tablet Drug: Venetoclax Oral Tablet

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 31, 2026

Target Sample Size: 44

Countries o...